



**Supplementary Fig. 1.** CD11b+Gr1+ cells of B16 tumor-bearing mice do not inhibit IFN- $\gamma$  production by NK cells. NK cells (2 x 10<sup>5</sup>) from naïve WT mice were co-cultured with or without CD11b+Gr1+ cells (2 x 10<sup>5</sup>) from spleen of B16 tumor-bearing mice. Cells were incubated with 50 ng/ml PMA and 2  $\mu$ g/ml ionomycin for 24 hours. IFN- $\gamma$  concentration in conditioned medium was determined.




**Supplementary Fig. 2.** CD11b+Gr1+ cells of EL4 tumor-bearing mice activate NK cells after polyl:C. EL4 thymoma cells  $(1x10^6)$  were implanted sc into B6 WT mice. After tumor formation, 200 μg polyl:C or PBS was injected i.p., CD11b+Gr1+ cells were isolated from spleen and co-cultured with naïve NK cells. IFN-α production from CD11b+Gr1+ cells, and NK cell CD69 expression and IFN-γ production was determined.

## B16 cells



**Supplementary Fig. 3.** Inhibition of B16 cell proliferation by IFN- $\gamma$ . B16D8 cells were seeded at 2 x 10<sup>4</sup> cells / 100  $\mu$ l in 96-well microplate and cultured for 24 hours in the presence of varying amounts of recombinant mouse IFN- $\gamma$  (Biolegend). Cell proliferation was determined by standard XTT assay.



**Supplementary Fig. 4.** Abrogation of NK cell activation by CD11b+Gr1+ cells in a transwell system. CD11b+Gr1+ cells were isolated from B16 tumor-bearing mice treated with polyl:C or PBS. A 0.4 μm transwell was inserted between CD11b+Gr1+ cells (2x10<sup>5</sup>) and NK cells (2x10<sup>5</sup>). CD69 expression on NK1.1+CD3ε- (**a**) and IFN-γ concentration in conditioned medium (**b**) was determined after the culturing for 24 hours.